Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patientsShuangtao Zhao, Preetesh Jain, Krystle Nomie et al.|American Journal of Hematology|2020Cited by 84
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Ke Yang et al.|Journal of Hepatology|2020Cited by 10